Abstract
Monascus or more commonly known as red mold rice is fermented rice on which Monascus purpureus has been grown. It has been a traditional Chinese food additive for thousands of years in China. Secondary metabolite product of Monascus, monacolin K, has been proven that it could be used as an antihypercholesterolemic agent. In this study, M. purpureus NTU568 mutated and selected from a monacolin K productivity strain—M. purpureus HM105 produced high quantities of monacolin K at a level of 9,500 mg kg−1. This research focused on the effect of adding red mold rice powder of M. purpureus NTU568 to a hamster diet on total cholesterol (TC), triglyceride (TG), high-density lipoprotein cholesterol, and low-density lipoprotein cholesterol (LDL-C). In the results, the oral administration of Monascus powder in hyperlipidemia hamster was indeed proven to decrease TC, TG, and LDL-C levels. Plasma TC levels in hamster fed with Monascus powder at onefold dosage [10.78 mg (day 100 g bw)−1] for 4 and 8 weeks were significantly lower (31.2 and 22.0%, respectively) than that in hyperlipidemia hamster. Plasma TG (30.1 and 17.9%) and LDL-C levels (36.0 and 20.7%) were also significantly lowered by feeding Monascus powder at onefold dosage for 4 and 8 weeks compared to hyperlipidemia hamster. In addition, examinations of liver TC and TG levels of hyperlipidemia hamster were also performed and showed similar effects on lipid-lowering action by oral administration of Monascus powder. Since citrinin is a mycotoxin that possesses nephrotoxic and hepatoxic effects, it has a negative impact on the safety of red mold rice for people. This study examined the liver somatic index [plasma glutamyl oxaloacetic transaminase (GOT) and glutamyl pyruvic transaminase (GPT) levels] and liver biopsy to investigate whether Monascus powder induced damage in liver. It was found that the plasma GOT and GPT levels were not significantly increased by feeding Monascus powder. There was no difference in the results of the liver biopsy between the Monascus powder-treated groups and the control group.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Aguilera CM, Ramirez-Tortosa CL, Quiles JL, Yago MD, Martinez-Burgos MA, Martinez-Victoria E, Gil A, Ramirez-Tortosa MC (2005) Monounsaturated and omega-3 but not omega-6 polyunsaturated fatty acids improve hepatic fibrosis in hypercholesterolemic rabbits. Nutrition 21:363–371
Albert AW, Chen J, Springer J (1980) Mevinolin: a highly potent competitive inhibitor of hydroxymethylglutaryl-coenzyme A reductase and a cholesterol lowering agent. Proc Natl Acad Sci U S A 77:3957–3961
American Institute of Nutrition (1977) Report of the American Institute of Nutrition ad hoc committee on standards for nutritional studies. J Nutr 107:1340–1348
Aniya Y, Ohtani II, Higa T, Miyagi C, Gibo H, Shimabukuro M, Nakanish H, Taira J (1999) Dimerumic acid as an antioxidant of the mold, Monascus anka. Free Radic Biol Med 286:999–1004
Blanc PJ, Laussac JP, Le Bars J, Le Bars P, Loret MO, Pareilleux A, Prome D, Prome JC, Santerre AL, Goma G (1995a) Characterization of monascidin A from Monascus as citrinin. Int J Food Microbiol 27:201–213
Blanc PJ, Loret MO, Goma G (1995b) Production of citrinin by various species of Monascus. Biotechnol Lett 17:291–294
Boyd E (1935) The growth of the surface area of human body. University of Minnesota Press, Minneapolis
Casas López JL, Sánchez Pérez JA, Fernández Sevilla JM, Acién Fernández FG, Molina Grima E, Chisti Y (2003) Production of lovastatin by Aspergillus terreus: effects of the C:N ratio and the principal nutrients on growth and metabolite production. Enzyme Microb Technol 33:270–277
Chang YN, Lin YC, Lee CC, Liu BL, Tzeng YM (2002) Effect of rice-glycerol complex medium on the production of lovastatin by Monascus ruber. Folia Microbiol (Praha) 47:677–684
Da Lozzo EJ, Oliveira MBM, Carnieri EGS (1998) Citrinin-induced mitochondrial permeability transition. J Biochem Mol Toxicol 12:291–297
Endo A (1979) Monacolin K, a new hypocholesterolemic agent produced by Monascus species. J Antibiot 32:852–854
Endo A, Hasumi K, Negishi S (1985) Monacolins J and L, new inhibitors of cholesterol biosynthesis produced by Monascus ruber. J Antibiot 38:420–422
Havel RJ, Hunninghake DB, Illingworth DR (1987) Lovastatin (mevinolin) in the treatment of heterozygous familial hypercholesterolemia. A multicenter study. Ann Intern Med 107:609–615
Hsieh YT, Pan TM (2002) The analytic methods and assays for secondary metabolites of Monascus products. J Biomass Energy Soc China 21:63–71
Jeong WI, Jeong DH, Do SH, Kim YK, Park HY, Kwon OD, Kim TH, Jeong KS (2005) Mild hepatic fibrosis in cholesterol and sodium cholate diet-fed rats. J Vet Med Sci 67:235–242
Lai LT, Pan CC, Tzeng BK (2003) The influence of medium design on lovastatin production and pellet formation with a high-producing mutant of Aspergillus terreus in submerged cultures. Proc Biochem 38:1317–1326
Lee CL, Wang JJ, Shing LK, Pan TM (2005) Study on the character and function of high monacolin K productivity mutant—Monascus purpureus NTU568. (Submitted to J Agric Food Chem)
Li CL, Zhu Y, Wang YY, Zhu JS, Chang J, Kritchevsky D (1998) Monascus purpureus-fermented rice (red yeast rice): a natural food product that lowers blood cholesterol in animal models of hypercholesterolemia. Nutr Res 18:71–81
Manzoni M, Rollini M (2002) Biosynthesis and biotechnological production of statins by filamentous fungi and application of these cholesterol-lowering drugs. Appl Microbiol Biotechnol 58:555–564
Manzoni M, Bergormi S, Rollini M, Cavazzoni V (1999) Production of statins by filamentous fungi. Biotechnol Lett 21:253–257
Michihara A, Sawamura M, Yamori Y, Akasaki K, Tsuji H (2003) Probucol decreases mevalonate pyrophosphate decarboxylase in the rat liver. Biol Pharm Bull 26:1484–1486
Noto H, Kawamura M, Hashimoto Y, Satoh H, Hara M, Iso-o N, Togo M, Kimura S, Tsukamoto K (2003) Modulation of HDL metabolism by probucol in complete cholesteryl ester transfer protein deficiency. Atherosclerosis 171:131–136
Papadia FS, Marinari GM, Camerini G, Murelli F, Carlini F, Stabilini C, Scopinaro N (2004) Liver damage in severely obese patients: a clinical–biochemical–morphologic study on 1,000 liver biopsies. Obes Surg 14:952–958
Schneweis I, Meyer K, Hormansdorfer S, Bauer J (2001) Metabolites of Monascus ruber in silages. J Anim Physiol Anim Nutr 85:38–44
Su YC, Wang JJ, Lin TT, Pan TM (2003) Production of the secondary metabolites γ-aminobutyric acid and monacolin K by Monascus. J Ind Microbiol Biotech 30:40–46
Wang UL, Houng JY, Chang HS, Chien CR, Hsu WH (1998) Selection of drug-resistant mutants Monascus pilosus for enhanced monacolin K production. J Chin Agric Chem Soc 36:192–200
Wang JJ, Lee CL, Pan TM (2003) Improvement of monacolin K, γ-aminobutyric acid and citrinin production ratio as a function of environmental conditions of Monascus purpureus NTU 601. J Ind Microbiol Biotech 30:669–676
Wong HC, Koehler PE (1981) Production and isolation of an antibiotic from Monascus purpureus and its relationship to pigment production. J Food Sci 46:589–592
Wu GF, Wu XC (2000) Screening DPPH radical scavengers from Monascus sp. Acta Microbiol Sin 40:394–399
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Lee, CL., Tsai, TY., Wang, JJ. et al. In vivo hypolipidemic effects and safety of low dosage Monascus powder in a hamster model of hyperlipidemia. Appl Microbiol Biotechnol 70, 533–540 (2006). https://doi.org/10.1007/s00253-005-0137-0
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00253-005-0137-0